Clinical trials: Recurrent Chronic Myelomonocytic Leukemia

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

• Completed
• Age: 18 years and older
• Injection or infusion
• Results posted

RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Trial name

NCT01233921

Testing

palifermin, flow cytometry, laboratory biomarker analysis

Where

United States

Volunteers

6 people

Sponsor

Martin, Paul